Ifnar2 Protein — Interferon Alpha Receptor 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Ifnar2 Protein — Interferon Alpha Receptor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ifnar2 Protein — Interferon Alpha Receptor 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Ifnar2 Protein — Interferon Alpha Receptor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
IFNAR2 exists in two isoforms: a membrane-bound receptor and a soluble receptor. The membrane form contains extracellular cytokine-binding domains, a transmembrane helix, and a cytoplasmic domain that recruits JAK1. The soluble form is generated by alternative splicing and proteolytic cleavage, acting as a natural antagonist of type I interferon signaling. IFNAR2 is the primary binding subunit for type I interferons.
Normal Function in the Nervous System
In the CNS, IFNAR2 mediates type I interferon responses:
Regulation of microglial antiviral responses
Modulation of astrocyte inflammatory signaling
Neuronal interferon responses during viral infections
Synaptic plasticity modulation through interferon-stimulated genes
Role in Disease
| Disease | Role | Mechanism | |---------|------|-----------| | Alzheimer's Disease | Risk factor | Chronic neuroinflammation through type I IFN signaling | | Parkinson's Disease | Risk factor | Altered interferon response in dopaminergic [neurons](/entities/neurons) | | Multiple Sclerosis | Therapeutic target | IFN-β therapy acts through IFNAR1/IFNAR2 | | Systemic Lupus Erythematosus | Biomarker | Elevated soluble IFNAR2 as disease marker |
Therapeutic Targeting
Soluble IFNAR2: Recombinant protein as therapeutic interceptor
JAK inhibitors: Downstream blockade
Interferon-blocking therapies: For chronic neuroinflammation
Key Publications
[21743993](https://pubmed.ncbi.nlm.nih.gov/21743993/): Type I IFN signaling. Nat Rev Immunol, 2011.
Ifnar2 Protein — Interferon Alpha Receptor 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Ifnar2 Protein — Interferon Alpha Receptor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
<references>
de Weerd NA, et al. (2011). Type I IFN receptor. Nat Rev Immunol 11: 503-517.
Goldmann T, et al. (2015). IFNAR in AD. Nat Neurosci 18: 1746-1755.